Navigation Links
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Date:12/9/2007

chloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival."

The data were derived from an analysis of the long-term outcomes of AML patients enrolled in the pivotal Phase III Ceplene study, which met its primary endpoint of increased LFS (p <0.01) among AML patients in remission. The objective of the five-year analysis was to assess the durability of the LFS benefit of post-consolidation immunotherapy with Ceplene + IL-2.

The median LFS of AML patients in first remission was 15 months for the Ceplene + IL-2 group versus 9.7 months in the control group (P=0.025). A Kaplan-Meier five-year estimate was supportive of the effect of Ceplene + IL-2 in maintaining LFS. In the AML population in first remission, this effect was shown in 34 percent of the treatment group versus 22 percent of the control group (P=0.024). Further, the median duration of the overall survival rate in the first remission patient group was 44 months for the Ceplene + IL-2 group versus 29 months for the control group, an improvement of 15 months. The Kaplan-Meier estimate analysis of patients alive at five years show a strong trend in favor of Ceplene + IL-2 (Kaplan-Meier, P=0.07), even though the trial was not initially powered to demonstrate a benefit in overall survival.

Dr. Brune stated, "The effect of a combined therapy of Ceplene + IL-2 in prolonging leukemia-free survival and in preventing relapse was both durable and statistically significant. These results indicate that Ceplene, if approved, could provide important therapeutic benefits to AML patients, for whom there are currently no available treatment options shown to increase leukemia-free survival."

Additional Ceplene Study Results Presented

In a separate poster presentation given yesterday at ASH, EpiCept provided new study results regarding the mechanisms of action relevant to Ceplene's demonstrated ability in combination with IL-2, to prevent leukemic relap
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. EpiCept Corporation Announces Pricing of Public Offering
10. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
11. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, survivor of a severe 1987 ... he recalled that his equipment was set up to depict the newly poured concrete. With ... bed. , The photo speaks for itself. Chatfield is also a highly praised safety and ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... blog post that encourages the understanding and treatment of ankle sprains. A common ... in-home remedies. This can be dangerous if the condition augments and causes more ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down ... in Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's ... on Thursday, September 17th at Ford Field in Detroit and the second match will ...
(Date:7/31/2015)... ... 31, 2015 , ... everMaya ( http://evermaya.com/ ), a Fashion ... will be named for Madeline Stuart, an 18-year-old model from Brisbane, Australia. Ms. ... with Down syndrome, gracing the front pages of publications across the world. everMaya ...
(Date:7/31/2015)... Detroit, MI (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable ... The U.S. Women's National Soccer Team will face the Australia Women's National Team in conjunction ... by a score of 5-2. Carli Lloyd from the USA team was awarded the ...
Breaking Medicine News(10 mins):Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... 26 Researchers at Wayne State University ... that may one day lead to new treatments.Prostate cancer, ... affects one in six men. In 2008, nearly ... nearly 186,000 were newly diagnosed, and approximately 28,000 died ...
... interactive pediatric healthcare education and resources for hospitals, physicians, and ... ... Wilmington, DE (PRWEB) March 26, 2009 -- Emmi Solutions ... and information programs, and KidsHealth ®, the largest provider ...
... Venture Capital Community to Drive Innovation through Investment Opportunities ... 26 The 510(k) program is under siege from ... complained in a letter to Congress that CDRH management ... 510(k)s. They followed that complaint to Congress with ...
... 26, 2009 Nearly 90 percent of the 700,000 strokes ... a blockage of blood vessels supplying the brain, known ... Catheterization and Cardiovascular Interventions , the official journal of ... solid evidence of the effectiveness of catheter-based therapy (CBT) ...
... a Mayo Clinic study show that a simple, noninvasive finger ... such as a heart attack or stroke, for people who ... study will be presented Tuesday, March 31, 2009 at 11:30 ... Annual Scientific Session in Orlando (0917-7).The noninvasive finger test device, ...
... Sure There,s a Rollover Bar Above Your Head , ... Bloomington, MN ... buyers of previously owned commercial zero-radius-turn (ZRT) mowers to check that each ... to a roll bar on a race car, an overhead ROPS and ...
Cached Medicine News:Health News:Wayne State University Scientists ID New Biomarker for Prostate Cancer 2Health News:Emmi + KidsHealth = Prescription for Informed and Involved Patients 2Health News:Emmi + KidsHealth = Prescription for Informed and Involved Patients 3Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 2Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 3Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 4Health News:Individualized stroke treatment available for patients, though underutilized 2Health News:Mayo Study Shows Simple Finger Device May Help Predict Future Heart Events, Such as Heart Attack 2Health News:Mayo Study Shows Simple Finger Device May Help Predict Future Heart Events, Such as Heart Attack 3Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 2Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 3Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 4Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 5
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015 ... research report with market overview, trends, DRO ... porter analysis, recent developments, competitive scenario and ... Industry Insight: Biosensors Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... Analysis of SPIRIT II and SPIRIT III Data Confirms Patients ... Death, a Heart Attack or a ... TAXUS(R) at Two Years, WASHINGTON, Oct. 13 Data ... randomized clinical,trials demonstrated that the XIENCE V(TM) Everolimus Eluting Coronary ...
... Class, of Stent with Polyzene(R)-F Surface ... for Long-Term,Dual Antiplatelet Therapy, WASHINGTON, ... today,s,"Innovative Devices and Futuristic Therapies" session ... (TCT) scientific,symposium, sponsored by the Cardiovascular ...
Cached Medicine Technology:Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 2Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 3Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 4Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 512-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: